Edition:
United Kingdom

Novus Therapeutics Inc (NVUS.OQ)

NVUS.OQ on NASDAQ Stock Exchange Capital Market

4.63USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$4.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,388
52-wk High
$6.50
52-wk Low
$3.13

Latest Key Developments (Source: Significant Developments)

Novus Therapeutics Reports Q4 Loss Per Share $0.30
Monday, 2 Apr 2018 

April 2 (Reuters) - Novus Therapeutics Inc ::YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.30.  Full Article

Andrew I. Mcdonald Reports 12.24 pct Passive Stake In Novus Therapeutics As Of March 9
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Novus Therapeutics Inc ::ANDREW I. MCDONALD REPORTS 12.24 PERCENT PASSIVE STAKE IN NOVUS THERAPEUTICS INC AS OF MARCH 9, 2018 - SEC FILING‍​.  Full Article

Novus Therapeutics Inc reported Q3 $0.43 loss per share​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Novus Therapeutics Inc :Novus Therapeutics Inc - ‍for Q3 of 2017, Novus reported $0.43 loss per share​.  Full Article

Novus Therapeutics reports third quarter 2017 results
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Novus Therapeutics Inc :Novus Therapeutics reports third quarter 2017 results.Q3 loss per share $0.43.  Full Article

Novus Therapeutics reports Q2 loss per share $1.32
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Novus Therapeutics Inc -:Novus Therapeutics reports second quarter 2017 results.Q2 loss per share $1.32.  Full Article

Ran Nussbaum reports 11.3 pct passive stake in Novus Therapeutics as of May 9
Thursday, 25 May 2017 

May 25 (Reuters) - Novus Therapeutics Inc :Ran nussbaum reports 11.3 percent passive stake in novus therapeutics inc as of may 9, 2017 - sec filing.  Full Article

Peregrine Ventures Management reports 8.9 percent passiave stake in Novus Therapeutics as of May 9
Monday, 22 May 2017 

May 22 (Reuters) - Peregrine Ventures Management Ltd :Peregrine Ventures Management Ltd reports a 8.9 percent passiave stake in Novus Therapeutics Inc as of May 9, 2017 - sec filing.  Full Article

Tokai pharmaceuticals inc says under terms of deal co may be required to pay Otic termination fee of $1 million
Thursday, 22 Dec 2016 

Tokai Pharmaceuticals Inc :Tokai Pharmaceuticals Inc says co may be required to pay Otic a termination fee of $1 million, or Otic may be required to pay co termination fee of $1.5 million.  Full Article

Tokai Pharmaceuticals and Otic Pharma enter into share purchase deal
Thursday, 22 Dec 2016 

Tokai Pharmaceuticals Inc : Tokai Pharmaceuticals and Otic Pharma enter into share purchase agreement . Tokai Pharmaceuticals Inc says upon exchange, it is expected that existing tokai stockholders will own approximately 40% of combined company . Tokai Pharmaceuticals - entered into a definitive share purchase agreement under which shareholders of otic pharma will become majority owners of tokai . Tokai Pharmaceuticals Inc - gregory j. Flesher to be named president and chief executive officer of combined company . Tokai Pharmaceuticals Inc - shareholders of otic pharma will receive a total of 32.2 million shares of newly issued tokai common stock . Transaction has been unanimously approved by boards of directors of both companies and shareholders of otic pharma . Tokai Pharmaceuticals Inc says existing otic pharma shareholders owning approximately 60% of combined company . Tokai Pharmaceuticals - upon close of transaction, board of combined cowill consist of 7 members, 3 to be designated by tokai, 4 to be designated by otic pharma .Tokai Pharmaceuticals - an otic pharma investor syndicate has committed to invest $7 million of additional capital in connection with share purchase agreement.  Full Article

Tokai Pharmaceuticals appoints John S. Mcbride CFO
Wednesday, 3 Aug 2016 

Tokai Pharmaceuticals Inc : Lee H. Kalowski, chief financial officer will cease employment effective august 31, 2016 - SEC filing . CFO, EVP, business operations and general counsel, will cease employment in relation to previously announced workforce reduction . Previously announced retirement of Karen J. Ferrante, chief medical officer, will become effective on august 31, 2016 .Appointed John S. Mcbride chief financial officer effective September 1, 2016.  Full Article

BRIEF-Novus Therapeutics Reports Q4 Loss Per Share $0.30

* Q4 LOSS PER SHARE $0.30 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)